Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

  • Etude concernée: IFCT-1501
  • Auteurs / Authors: Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Olivier Molinier, Luc Thiberville, Thierry Urban, Catherine Ligeza-poisson, David Planchard, Elodie Amour, Franck Morin, Denis Moro-Sibilot, Gerard Zalcman
  • Journal / Conference: ASCO
  • Année / Year: 2017
  • PMID: Oral abstract
  • Lien vers la publication: https://ascopubs.org/doi/abs/10.1200/jco.2017.35.18_suppl.lba8507